P1,P5-Di(adenosine-5′) pentaphosphate pentasodium salt

• Catalog No.: 31588
• CAS Number: 4097-04-5
• M. F.: C20H24N10Na5O22P5
• M. W.: 1026.276015
• Purity: ≥96.0% (HPLC)

SYNONYMS

• IUPAC name: pentasodium ({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphonato}oxy)[({[({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphonato}oxy)phosphinato]oxy}phosphinato)oxy]phosphinate
• IUPAC Traditional name: pentasodium Ap5A
• Synonyms: Diadenosine pentaphosphate pentasodium salt; A(5′)P5(5′)A

DATABASE IDS

• Beilstein Number: 4949216
• CAS Number: 4097-04-5
• MDL Number: MFCD00077718
• EC Number: 223-852-7

PROPERTIES

• Linear Formula: C20H29N10O22P5 · 5 Na
• Purity: ≥96.0% (HPLC)
• Solubility: H2O: soluble50 mg/mL, clear, slightly yellow
• Personal Protective Equipment: Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter
• Storage Temperature: -20°C
• German water hazard class: 3

DETAILS

Description (English)

Biochem/physiol Actions
A diadenosine polyphosphate stored in secretory granules of thrombocytes, chromaffin and neuronal cells. After release into the extracellular space, it affects a variety of biological activities in a wide range of target tissues. In the nervous system it acts through various purinergic receptors. It also activates 5′-nucleotidase and inhibits adenosine kinase activity in vitro. Ap5A is metabolized by soluble enzymes in the blood plasma and by membrane-bound ectoenzymes of a number of cell types including endothelial and smooth muscle cells. In cardiac muscle, pM to nM concentrations significantly increase the open-probability of ryanodine-receptor (RyR2) gates, with prolonged action due to slow dissociation from the receptor.1

Description (简体中文)

Biochem/physiol Actions
A diadenosine polyphosphate stored in secretory granules of thrombocytes, chromaffin and neuronal cells. After release into the extracellular space, it affects a variety of biological activities in a wide range of target tissues. In the nervous system it acts through various purinergic receptors. It also activates 5′-nucleotidase and inhibits adenosine kinase activity in vitro. Ap5A is metabolized by soluble enzymes in the blood plasma and by membrane-bound ectoenzymes of a number of cell types including endothelial and smooth muscle cells. In cardiac muscle, pM to nM concentrations significantly increase the open-probability of ryanodine-receptor (RyR2) gates, with prolonged action due to slow dissociation from the receptor.1